Details of the Drug
General Information of Drug (ID: DM7W25U)
| Drug Name |
1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL370779; 1-(phenylsulfonyl)-4-(1-piperazinyl)-1h-indole; 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole; 412049-71-9; 1-Benzenesulfonyl-4-piperazin-1-yl-1H-indole; SCHEMBL1136504; ZINC3210; DTXSID90436238; OPAMDWUUNKYGOR-UHFFFAOYSA-N; BDBM50174269; 1-(phenylsulfonyl)-4-piperazin-1-yl-indole; FT-0724295; 1-(benzenesulfonyl)-4-(1-piperazinyl)indole; 1-(phenylsulfonyl)-4-piperzin-1-yl-1H-indole; 1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole; 1-(phenylsulfonyl)-4-piperazin-1-y1-1H-indole
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 341.4 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


